Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice

Markos, James; Harris, Hannah M.; Gul, Waseem; ElSohly, Mahmoud A.; Sufka, Kenneth J.

doi:10.1055/s-0043-117838

Cited by 35 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…THC itself was demonstrated to be more effective than CBD in inhibiting morphine abstinence syndrome in mice (137, 138). Nevertheless, more recent studies demonstrate that treatment with CBD blocked the reward-facilitating effect of morphine (132), reduced morphine CPP and CPA, and prevented drug and stress-induced reinstatement of CPP (71, 127). CBD was also found to have some efficacy in heroin studies in rats.…”

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

et al. 2019

View full text Add to dashboard Cite

Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol (CBD), a non-psychoactive phytocannabinoid found in the cannabis plant, has also been proposed as a potentially effective treatment for the management of substance use disorder. Animal and human studies suggest that these cannabinoids have the potential to reduce craving and relapse in abstinent substance users, by impairing reconsolidation of drug-reward memory, salience of drug cues, and inhibiting the reward-facilitating effect of drugs. Such functions likely arise through the targeting of the endocannabinoid and serotonergic systems, although the exact mechanism is yet to be elucidated. This article seeks to review the role of the endocannabinoid system in substance use disorder and the proposed pharmacological action supporting cannabinoid drugs' therapeutic potential in addictions, with a focus on CBD. Subsequently, this article will evaluate the underlying evidence for CBD as a potential treatment for substance use disorder, across a range of substances including nicotine, alcohol, psychostimulants, opioids, and cannabis. While early research supports CBD's promise, further investigation and validation of CBD's efficacy, across preclinical and clinical trials will be necessary.

show abstract

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 140 Administration of CBD also attenuates morphine CPP and cue-induced reinstatement of heroin self-administration in rats, without creating any aversive or rewarding effects on its own. 106 , 141–143 …”

Section: Cannabis As a Harm Reduction Tool In Oudmentioning

confidence: 99%

Emerging Evidence for Cannabis' Role in Opioid Use Disorder

Wiese

Wilson-Poe

2018

Cannabis and Cannabinoid Research

128

View full text Add to dashboard Cite

Introduction: The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive.Discussion: Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for all patients. Furthermore, there are legal and logistical bottlenecks to obtaining traditional opioid replacement therapies such as methadone or buprenorphine, and the demand for these services far outweighs the supply and access. To fill the gap between efficacious OUD treatments and the widespread prevalence of misuse, relapse, and overdose, the development of novel, alternative, or adjunct OUD treatment therapies is highly warranted. In this article, we review emerging evidence that suggests that cannabis may play a role in ameliorating the impact of OUD. Herein, we highlight knowledge gaps and discuss cannabis' potential to prevent opioid misuse (as an analgesic alternative), alleviate opioid withdrawal symptoms, and decrease the likelihood of relapse.Conclusion: The compelling nature of these data and the relative safety profile of cannabis warrant further exploration of cannabis as an adjunct or alternative treatment for OUD.

show abstract

“…Indeed, given the increased abuse of prescription opiates, research examining the interplay between the endogenous cannabinoid and opioid systems could potentially prevent the transition of using marijuana to opiates. This research field has been of increasing interest; for example, the interplay between cannabidiol and morphine has been examined in mice 66 . Thus, it remains possible that priming of THC is specific to drugs targeting the opioid system.…”

Section: Discussionmentioning

confidence: 99%

Adolescent THC exposure does not sensitize conditioned place preferences to subthreshold d-amphetamine in male and female rats

et al. 2018

View full text Add to dashboard Cite

The acute effects of marijuana consumption on brain physiology and behaviour are well documented, but the long-term effects of its chronic use are less well known. Chronic marijuana use during adolescence is of increased interest, given that the majority of individuals first use marijuana during this developmental stage , and adolescent marijuana use is thought to increase the susceptibility to abusing other drugs when exposed later in life. It is possible that marijuana use during critical periods in adolescence could lead to increased sensitivity to other drugs of abuse later on. To test this, we chronically administered ∆ 9-tetrahydrocannabinol (THC) to male and female Long-Evans (LER) and Wistar (WR) rats directly after puberty onset. Rats matured to postnatal day 90 before being exposed to a conditioned place preference task (CPP). A subthreshold dose of d-amphetamine, found not to induce place preference in drug naïve rats, was used as the unconditioned stimulus. The effect of d-amphetamine on neural activity was inferred by quantifying cfos expression in the nucleus accumbens and dorsal hippocampus following CPP training. Chronic exposure to THC post-puberty had no potentiating effect on a subthreshold dose of d-amphetamine to induce CPP. No differences in cfos expression were observed. These results show that chronic exposure to THC during puberty did not increase sensitivity to a sub-threshold dose of d-amphetamine in adult LER and WR rats. This supports the concept that THC may not sensitize the response to all drugs of abuse.

show abstract

Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice

Cited by 35 publications

References 25 publications

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

Emerging Evidence for Cannabis' Role in Opioid Use Disorder

Adolescent THC exposure does not sensitize conditioned place preferences to subthreshold d-amphetamine in male and female rats

Contact Info

Product

Resources

About